



**May 9, 2024**

**BSE Ltd.,**  
P J Towers,  
Dalal Street,  
Mumbai - 400 001.  
**Scrip Code: 524735**

**National Stock Exchange of India Ltd.,**  
Exchange Plaza,  
Bandra-Kurla Complex, Bandra,  
Mumbai - 400 051.  
**Symbol: HIKAL**

Dear Sir/Madam,

**Subject: Results Presentation of the Company for the quarter and financial year ended March 31, 2024**

With reference to the subject, we are enclosing a copy of the Results presentation on the Audited Standalone and Consolidated Financial Results of the Company for the quarter and Financial year ended March 31, 2024.

This is for your information and records.

Thank you,

Yours sincerely,  
**for HIKAL LIMITED,**

**Rajasekhar Reddy**  
**Company Secretary & Compliance Officer**

**Encl: As above**

**Hikal Ltd.**

**Admin. Office:** Great Eastern Chambers, 6<sup>th</sup> Floor, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India. Tel. + 91-22-6277 0299, + 91-22-6866 0300

**Regd. Office:** 717, Maker Chambers - 5, Nariman Point, Mumbai - 400 021, India. Tel. +91-22 6277 0477. Fax: + 91-22 6277 0500

www.hikal.com    info@hikal.com    CIN: L24200MH1988PTC048028



*Results Presentation - Q4 FY24*

This presentation and the accompanying slides (the “Presentation”), which have been prepared by Hikal Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.



Jai Hiremath

“For the financial year '24, we achieved revenues of Rs 1,785 Crores as compared to Rs 2,023 Crores last year. FY24 was marred with several global macroeconomic pressures and depressed market conditions for the global chemical sector on account of inventory build up and overcapacity across the sector resulting in intense price competition from China predominantly in the Crop Protection market.

Our Board of Directors has recommended a final dividend of Rs 0.60 per share (30%). Along with an interim dividend of Rs. 0.60 per share (30%) declared in February 2024, the total dividend for FY24 stands at Rs 1.20 per share (60% of FV).

For Q4 FY24, our pharmaceutical business reported revenue growth of 26% to Rs 338 Cr and EBIT growth of 191% to Rs 54 Cr, on QoQ basis. In the API segment, we witnessed increased volume off-take based on higher demand from existing customers and from newer geographies. This coupled with stabilized raw material prices have supported us in maintaining our margin profile. In our CDMO segment we have received several RFP's from both emerging pharma and global innovators, with several products progressing through the development stages. We have a healthy pipeline of projects in the early to mid-phase that is encouraging. During FY24, our API facility in Panoli, Gujarat, was audited by the US FDA, and the audit was concluded with 'Zero' 483 observations as a testament of our commitment to high standards of regulatory compliance.

For Q4FY24, our crop protection business reported revenue of Rs 177 Cr and EBIT of Rs 14 Cr. Despite proactive cost improvement initiatives, the global crop protection industry continues to face significant headwinds, including subdued global demand due to inventory in the channel pipeline and intense price erosion from competitors primarily China as a result of large capacity which are under-utilized. We expect the market to stabilize post the end of this financial year and recovery to begin thereafter.

In our animal health business, advancements in developing a portfolio of products under a long-term agreement with an innovator animal health company are proceeding well. During the third quarter, our new multipurpose animal health facility was commissioned at Panoli, Gujarat. Validation of several products is underway, and it is scheduled to be completed in the upcoming quarters. These validation batches mark the initial phase toward product registration and subsequent commercialization.

Under our strategic transformation initiative - Pinnacle, we have taken substantial strides toward sustaining growth across our various businesses. We have gained momentum in supply chain derisking, developing differentiated capabilities, the acquisition of new customers and the building of a distinctive technology platform. As we navigate through the next stage of our strategic plan, our focus is directed more towards the front-end capitalizing on the opportunities to build a healthy pipeline for our businesses.

Despite the current challenging global conditions, we anticipate a favorable shift in market dynamics over the mid to long term, and we remain focused in our strategy to deliver profitable, and sustainable growth across our businesses.”



## *Quarterly Financials Highlights*

# Gradual Recovery in Q4 - sequential improvement in revenues and margins



Revenue - Q4 FY24  
Rs. 514 Crore



YoY  
6%



QoQ  
15%



EBITDA - Q4 FY24  
Rs. 94 Crore



YoY  
7%



QoQ  
45%



EBITDA Margin - Q4 FY24  
18.4%



YoY  
220 bps



QoQ  
390 bps



PAT - Q4 FY24  
Rs. 34 Crore



YoY  
6%



QoQ  
108%



EPS - Q4 FY24  
Rs 2.75




YoY  
6%



QoQ  
108%


## Quarterly Performance Highlights



Rs. Crore

### Performance Highlights

- Revenue recorded at Rs 514 Crore, 15% growth QoQ basis
  - Change in product mix
  - Increased demand of Own products in Pharmaceutical segment
- EBITDA stood at Rs 94 Crore, 45% increase on QoQ basis
  - EBITDA margins improved by 390bps on a QoQ basis
  - Sequential QoQ recovery in margins on back of softening of raw material prices and several operational improvement initiatives
- PAT was Rs. 34 Crore, 108% increase on QoQ basis
  - Improved business profitability driven by better product mix
- Hikal's long term credit rating is maintained at A+ by ICRA




Rs. Crore

### Pharmaceuticals - Performance Highlights

- Revenue recorded at Rs 338 Crore, 26% growth QoQ basis
  - Change in product mix
  - Increased demand of Own products in Pharmaceutical segment
- EBIT stood at Rs 54 Crore, sequential growth of 191%
  - EBIT margins improved by 900bps on a QoQ basis
  - Softening of key RM prices
  - Improvement on account of business excellence initiatives
- Animal Health
  - Four products are validated as per plan & several other products are under validation and expected to be completed in upcoming few quarters
- Good traction in Own Products from customers in Japan, Latin America and Middle East geographies for the newer product portfolio
- New opportunities are under advanced stage of discussion with various global innovators in CDMO business



# Quarterly Performance Highlights - Crop Protection



## Crop Protection - Performance Highlights

- Revenue stood flat at Rs 177 Crore on QoQ basis
  - Overcapacity and high channel inventory situation continues to affect at an Industry level
  - Operating environment is expected to stabilize towards the end of financial year
- EBIT stood at Rs 14 Crore, 37% degrowth on QoQ basis
  - Intense price erosion from competitors primarily from China
- Commissioning activity is going as per plan at the new multipurpose facility at Panoli, Gujarat.
- We have a strong pipeline of opportunities under discussion with various global innovators




# Quarterly Financial Highlights



### Consolidated Revenue


### Consolidated EBITDA

### Consolidated PAT




# Quarterly Segmental Highlights


Pharmaceuticals Revenue




Crop Protection Revenue



Pharmaceuticals EBIT



Crop Protection EBIT



## Consolidated Profit & Loss - Q4 FY24

Particulars (Rs. Crore)	Q4 FY24	Q4 FY23	Y-o-Y	Q3 FY24	Q-o-Q
<b>Net Sales</b>	<b>514</b>	<b>544</b>	<b>-6%</b>	<b>448</b>	<b>15%</b>
Expenditure	420	556		283	
<b>EBITDA</b>	<b>94</b>	<b>88</b>	<b>7%</b>	<b>65</b>	<b>45%</b>
<b>Margin</b>	<b>18.4%</b>	<b>16.2%</b>		<b>14.5%</b>	
Other Income	0	0		0	
Depreciation	32	27		29	
Finance Costs	15	13		14	
<b>PBT</b>	<b>47</b>	<b>49</b>	<b>-3%</b>	<b>22</b>	<b>117%</b>
Tax	13	13		5	
<b>Net Profit</b>	<b>34</b>	<b>36</b>	<b>-6%</b>	<b>16</b>	<b>108%</b>
<b>Margin</b>	<b>6.6%</b>	<b>3.6%</b>		<b>6.6%</b>	



**Annual Financials Highlights**

## Financial Highlights - Annual



Revenue – FY24  
Rs. 1,785 Crore

↓ YoY  
-12%



EBITDA – FY24  
Rs. 267 Crore

↑ YoY  
+4%



EBITDA Margin – FY24  
15.0%

↑ YoY  
+230 bps



PAT – FY24  
Rs. 70 Crore


↓ YoY  
-11%




EPS – FY24  
Rs 5.64

↓ YoY  
-11%


# Annual Performance Highlights



## Pharmaceuticals Division



## Crop Protection Division






# Yearly Financial Highlights



### Consolidated Revenue

### Consolidated EBITDA

### Consolidated PAT



Rs. Crore




# Sales Break-Up




- CDMO
- Own products


### Company Revenue Break-Up



### Pharmaceuticals Revenue Break-Up




### Crop Protection Revenue Break-Up




# Yearly Segmental Highlights


Pharmaceuticals Revenue




Crop Protection Revenue



Pharmaceuticals EBIT



Crop Protection EBIT



## Consolidated Profit & Loss - Full Year

Particulars (Rs. Crore)	FY24	FY23	Y-o-Y
<b>Net Sales</b>	<b>1,785</b>	<b>2,023</b>	<b>-12%</b>
Expenditure	1,518	1,766	
<b>EBITDA</b>	<b>267</b>	<b>257</b>	<b>+4%</b>
<b>Margin</b>	<b>15.0%</b>	<b>12.7%</b>	<b>230 bps</b>
Other Income	2	5	
Depreciation	118	109	
Finance Costs	56	48	
Exceptional Item	-	-	
<b>PBT</b>	<b>95</b>	<b>105</b>	<b>-9%</b>
Tax	26	27	
<b>Net Profit</b>	<b>70</b>	<b>78</b>	<b>-11%</b>
<b>Margin</b>	<b>3.9%</b>	<b>3.9%</b>	<b>-</b>

## Consolidated Balance Sheet



Assets (Rs. Crore)	Mar-24	Mar-23
<b>Total Non Current Assets</b>	<b>1,521</b>	<b>1,446</b>
Property, Plant and Equipment	996	885
Capital work in Progress	414	402
Right to Use Assets	65	63
Other Intangible Assets	10	-
Intangible Assets Under Development	-	10
Financial Assets		
Investments	5	5
Loans	-	-
Other	16	19
Income Tax Assets (Net)	2	2
Other Non Current Assets	12	60
<b>Total Current Assets</b>	<b>967</b>	<b>939</b>
Inventories	304	317
Financial Assets		
Current Investment	-	-
Trade Receivables	550	442
Cash & Cash Equivalents	13	27
Bank Balances	8	33
Loans	-	-
Other	14	17
Other Current Assets	78	104
<b>TOTAL ASSETS</b>	<b>2,487</b>	<b>2,386</b>





Equities & Liabilities (Rs. Crore)	Mar-24	Mar-23
<b>Shareholders Fund</b>	<b>1,188</b>	<b>1,134</b>
Share Capital	25	25
Other Equity	1,163	1,109
<b>Total Non Current Liabilities</b>	<b>543</b>	<b>590</b>
Financial Liabilities		
Borrowings	423	490
Lease Liability	3	-
Provisions	28	24
Deferred Tax Liabilities (net)	30	33
Other non current liabilities	59	44
<b>Total Current Liabilities</b>	<b>757</b>	<b>662</b>
Financial Liabilities		
Borrowings	392	258
Lease Liability	-	-
Trade Payables	279	313
Other Financial Liabilities	41	49
Other Current Liabilities	29	24
Provisions	4	3
Current Tax Liabilities (Net)	12	14
<b>TOTAL EQUITY &amp; LIABILITIES</b>	<b>2,487</b>	<b>2,386</b>

## Consolidated Cash Flow Statement



Particulars (Rs. Crore)	Full Year ended 31-Mar-24	Full Year ended 31-Mar-23
Profit before tax	95	105
<i>Adjustments</i>	175	163
Operating Profit Before Working Capital Changes	270	268
<i>Change in operating assets and liabilities</i>	(53)	76
Cash generated from operations	217	344
<i>Income taxes paid</i>	(30)	(29)
<b>Net cash inflow from operating activities (A)</b>	<b>187</b>	<b>315</b>
<b>Net cash inflow/(outflow) from investing activities (B)</b>	<b>(174)</b>	<b>(292)</b>
<b>Net cash outflow from financing activities (C)</b>	<b>(27)</b>	<b>(8)</b>
<b>Net increase/(decrease) in cash and cash equivalents (A+B+C)</b>	<b>(14)</b>	<b>15</b>
<b>Cash and cash equivalents at the beginning of the year</b>	<b>27</b>	<b>11</b>
<b>Cash and cash equivalents at the end of the year</b>	<b>13</b>	<b>27</b>

# Ratio Analysis




# Annual Dividend Payout



Dividend Payout including DDT

22% 18% 19% 17% 20% 19% 19% 12% 19% 21%



The above dividend is based on Face Value of Rs. 2 per share



**Company :**

**Hikal Limited**  
**CIN: L24200MH1988PTC048028**

Mr. Kuldeep Jain

[kuldeep\\_jain@hikal.com](mailto:kuldeep_jain@hikal.com)

[www.hikal.com](http://www.hikal.com)

**SGA** Strategic Growth Advisors

**Investor Relations Advisors :**

**Strategic Growth Advisors Pvt. Ltd.**  
**CIN: U74140MH2010PTC204285**

Mr. Jigar Kavaiya / Ms. Ami Parekh  
+91-9920602034 / +91-8082466052  
[jigar.kavaiya@sgapl.net](mailto:jigar.kavaiya@sgapl.net) / [ami.parekh@sgapl.net](mailto:ami.parekh@sgapl.net)

[www.sgapl.net](http://www.sgapl.net)



**HIKAL**

---